Home > Healthcare > Pharmaceuticals > Finished Drug Form > Neutropenia Treatment Market

Neutropenia Treatment Market Size

Report ID: GMI8441
Published Date: Mar 2024
Report Format: PDF

Download Free Sample

Neutropenia Treatment Market Size

Neutropenia Treatment Market was valued at USD 14.5 billion in 2023 and is set to grow at over 4.1% CAGR from 2024 to 2032, driven by the increasing prevalence of neutropenia, marked by abnormally low neutrophil levels which intensified the demand for neutropenia treatment. Additionally, the rising incidence of disorders like cancer and autoimmune diseases, leading to neutropenia, further fuelled the demand for effective treatment, contributing to market growth.

To get key market trends

Download Free Sample

Neutropenia treatment refers to the therapeutic interventions to manage and alleviate the condition characterized by abnormally low levels of neutrophils, a type of white blood cell crucial for the body's immune response. The treatment approaches involve addressing the underlying cause of neutropenia, such as chemotherapy-induced myelosuppression function, autoimmune disorders, or congenital conditions.

Neutropenia Treatment Market Report Attributes
Report Attribute	Details
Base Year:	2023
Neutropenia Treatment Market Size in 2023:	USD 14.5 Billion
Forecast Period:	2024 to 2032
Forecast Period 2024 to 2032 CAGR:	4.1%
2032 Value Projection:	USD 20.8 Billion
Historical Data for:	2018 – 2023
No. of Pages:	170
Tables, Charts & Figures:	260
Segments covered:	Treatment Type, Drug Type, Route of Administration, Indication, Distribution Channel, and Region
Growth Drivers:	Increasing prevalence of neutropenia Growing utilization of chemotherapy Government initiatives and support aimed at raising awareness Rising R&D efforts expand robust drug pipeline Increasing advancements in pharmaceutical drug delivery technology Favorable reimbursement policies support treatment accessibility
Pitfalls & Challenges:	Stringent regulations for product approvals Adverse effects associated with the treatment

Learn more about the key segments shaping this market

Download Free Sample

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The market size of neutropenia treatment was reached USD 14.5 billion in 2023 and is expected to register over 4.1% CAGR from 2024 to 2032, owing to the increasing prevalence of neutropenia, marked by abnormally low neutrophil levels which intensified the demand for neutropenia treatment worldwide.

Neutropenia treatment industry from the colony-stimulating factors segment is set to exceed USD 13 billion by 2032, due to its ability to stimulate the production of white blood cells, specifically neutrophils, which are crucial for combating infections.

North America neutropenia treatment industry is expected to record USD 7.4 billion by 2032 due to increasing cancer prevalence, demand for disease-specific treatment, robust healthcare spending, well-established infrastructure, and the presence of key market players in the region.

Biocon Biologics Inc., Cellerant Therapeutics, Coherus BioSciences, Inc., CuraTeQ Biologics Pvt. Ltd., Evive Biotech, Kyowa Kirin Co., Ltd., Pfizer Inc., Sandoz Inc., Spectrum Pharmaceuticals, and Teva Pharmaceutical Industries Ltd. are some of the major neutropenia treatment companies worldwide.